Deficiency of Monoacylglycerol Lipase Enhances IgM Plasma Levels and Limits Atherogenesis in a CB2-Dependent Manner

Raquel Guillamat Prats; Martina Rami; Larisa Ring; Petteri Rinne; Estelle Lauer; Sebastien Lenglet; Aurelien Thomas; Sabrina Pagano; Nicolas Vuilleumier; Benjamin F. Cravatt; Christian Weber; Alexander Faussner; Sabine Steffens

doi:10.1055/s-0038-1676769

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2019; 119(02): 348-351
DOI: 10.1055/s-0038-1676769

Letter to the Editor

Georg Thieme Verlag KG Stuttgart · New York

Deficiency of Monoacylglycerol Lipase Enhances IgM Plasma Levels and Limits Atherogenesis in a CB2-Dependent Manner

Raquel Guillamat Prats^*

¹Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians University (LMU) of Munich, Munich, Germany

,

Martina Rami^*

¹Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians University (LMU) of Munich, Munich, Germany

,

Larisa Ring^*

¹Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians University (LMU) of Munich, Munich, Germany

,

Petteri Rinne

¹Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians University (LMU) of Munich, Munich, Germany

²Institute of Biomedicine, University of Turku, Turku, Finland

,

Estelle Lauer

³Unit of Toxicology, CURML, Lausanne University Hospital, Geneva University Hospitals, Geneva, Switzerland

,

Sebastien Lenglet

³Unit of Toxicology, CURML, Lausanne University Hospital, Geneva University Hospitals, Geneva, Switzerland

,

Aurelien Thomas

³Unit of Toxicology, CURML, Lausanne University Hospital, Geneva University Hospitals, Geneva, Switzerland

⁴Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland

,

Sabrina Pagano

⁵Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland

,

Nicolas Vuilleumier

⁵Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland

,

Benjamin F. Cravatt

⁶Department of Chemical Physiology, The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California, United States

,

Christian Weber

¹Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians University (LMU) of Munich, Munich, Germany

⁷German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany

⁸Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands

,

Alexander Faussner

¹Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians University (LMU) of Munich, Munich, Germany

,

Sabine Steffens

¹Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians University (LMU) of Munich, Munich, Germany

⁷German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany

› Author Affiliations

Abstract

Full Text

References

References
1 Pacher P, Steffens S. The emerging role of the endocannabinoid system in cardiovascular disease. Semin Immunopathol 2009; 31 (01) 63-77
2 Montecucco F, Matias I, Lenglet S. , et al. Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis. Atherosclerosis 2009; 205 (02) 433-441
3 Sugamura K, Sugiyama S, Nozaki T. , et al. Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation 2009; 119 (01) 28-36
4 Wang PF, Jiang LS, Bu J. , et al. Cannabinoid-2 receptor activation protects against infarct and ischemia-reperfusion heart injury. J Cardiovasc Pharmacol 2012; 59 (04) 301-307
5 Weis F, Beiras-Fernandez A, Sodian R. , et al. Substantially altered expression pattern of cannabinoid receptor 2 and activated endocannabinoid system in patients with severe heart failure. J Mol Cell Cardiol 2010; 48 (06) 1187-1193
6 Quercioli A, Pataky Z, Vincenti G. , et al. Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. Eur Heart J 2011; 32 (11) 1369-1378
7 Vujic N, Schlager S, Eichmann TO. , et al. Monoglyceride lipase deficiency modulates endocannabinoid signaling and improves plaque stability in ApoE-knockout mice. Atherosclerosis 2016; 244: 9-21
8 Montecucco F, Di Marzo V, da Silva RF. , et al. The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. Eur Heart J 2012; 33 (07) 846-856
9 Steffens S, Veillard NR, Arnaud C. , et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 2005; 434 (7034): 782-786
10 Hoyer FF, Steinmetz M, Zimmer S. , et al. Atheroprotection via cannabinoid receptor-2 is mediated by circulating and vascular cells in vivo. J Mol Cell Cardiol 2011; 51 (06) 1007-1014
11 Vujic N, Korbelius M, Leopold C. , et al. Monoglyceride lipase deficiency affects hepatic cholesterol metabolism and lipid-dependent gut transit in ApoE-/- mice. Oncotarget 2017; 8 (20) 33122-33136
12 Jehle J, Schöne B, Bagheri S. , et al. Elevated levels of 2-arachidonoylglycerol promote atherogenesis in ApoE-/- mice. PLoS One 2018; 13 (05) e0197751
13 Quercioli A, Montecucco F, Pataky Z. , et al. Improvement in coronary circulatory function in morbidly obese individuals after gastric bypass-induced weight loss: relation to alterations in endocannabinoids and adipocytokines. Eur Heart J 2013; 34 (27) 2063-2073
14 Thomas A, Hopfgartner G, Giroud C, Staub C. Quantitative and qualitative profiling of endocannabinoids in human plasma using a triple quadrupole linear ion trap mass spectrometer with liquid chromatography. Rapid Commun Mass Spectrom 2009; 23 (05) 629-638
15 Schlosburg JE, Blankman JL, Long JZ. , et al. Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci 2010; 13 (09) 1113-1119
16 Horckmans M, Bianchini M, Santovito D. , et al. Pericardial adipose tissue regulates granulopoiesis, fibrosis, and cardiac function after myocardial infarction. Circulation 2018; 137 (09) 948-960
17 Tsiantoulas D, Sage AP, Mallat Z, Binder CJ. Targeting B cells in atherosclerosis: closing the gap from bench to bedside. Arterioscler Thromb Vasc Biol 2015; 35 (02) 296-302
18 Rosenfeld SM, Perry HM, Gonen A. , et al. B-1b cells secrete atheroprotective IgM and attenuate atherosclerosis. Circ Res 2015; 117 (03) e28-e39
19 Kyaw T, Tay C, Krishnamurthi S. , et al. B1a B lymphocytes are atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in atherosclerotic lesions. Circ Res 2011; 109 (08) 830-840
20 Fiskesund R, Su J, Bulatovic I, Vikström M, de Faire U, Frostegård J. IgM phosphorylcholine antibodies inhibit cell death and constitute a strong protection marker for atherosclerosis development, particularly in combination with other auto-antibodies against modified LDL. Results Immunol 2012; 2: 13-18
21 de Faire U, Frostegård J. Natural antibodies against phosphorylcholine in cardiovascular disease. Ann N Y Acad Sci 2009; 1173: 292-300
22 Berliner JA, Subbanagounder G, Leitinger N, Watson AD, Vora D. Evidence for a role of phospholipid oxidation products in atherogenesis. Trends Cardiovasc Med 2001; 11 (3-4): 142-147
23 Long JZ, Nomura DK, Cravatt BF. Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. Chem Biol 2009; 16 (07) 744-753
24 Kinsey SG, Wise LE, Ramesh D. , et al. Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects. J Pharmacol Exp Ther 2013; 345 (03) 492-501
25 Grabner GF, Zimmermann R, Schicho R, Taschler U. Monoglyceride lipase as a drug target: at the crossroads of arachidonic acid metabolism and endocannabinoid signaling. Pharmacol Ther 2017; 175: 35-46

Supplementary Material

Supplementary Material